Michael Haberland
Overview
Explore the profile of Michael Haberland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
2429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
George W, Steffen P, Blum K, Schanze T, Larionov P, Weber K, et al.
MMW Fortschr Med
. 2021 Aug;
163(Suppl 5):3-11.
PMID: 34383281
Background: About 80% of all people in Germany die in inpatient care. Around every fifth person in inpatient care is relocated to another care area in the last phase of...
2.
Keller J, Catala-Lehnen P, Huebner A, Jeschke A, Heckt T, Lueth A, et al.
Nat Commun
. 2014 Oct;
5:5215.
PMID: 25333900
The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about...
3.
Haberland M, Carrer M, Mokalled M, Montgomery R, Olson E
J Biol Chem
. 2010 Mar;
285(19):14663-70.
PMID: 20190228
Adipocyte differentiation is a well defined process that is under the control of transcriptional activators and repressors. We show that histone deacetylase (HDAC) inhibitors efficiently block adipocyte differentiation in vitro....
4.
Haberland M, Mokalled M, Montgomery R, Olson E
Genes Dev
. 2009 Jul;
23(14):1625-30.
PMID: 19605684
Histone deacetylases (Hdacs) are transcriptional repressors with crucial roles in mammalian development. Here we provide evidence that Hdac8 specifically controls patterning of the skull by repressing a subset of transcription...
5.
Haberland M, Johnson A, Mokalled M, Montgomery R, Olson E
Proc Natl Acad Sci U S A
. 2009 May;
106(19):7751-5.
PMID: 19416910
Histone deacetylase inhibitors (HDACi) represent a new group of drugs currently being tested in a wide variety of clinical applications. They are especially effective in preclinical models of cancer where...
6.
Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, et al.
Circ Res
. 2009 Feb;
104(7):851-9.
PMID: 19246678
The characteristics of dilated cardiomyopathy (DCM) resulting from chronic viral myocarditis are remodeling processes of the extracellular matrix. Based on our findings of enhanced osteopontin (OPN) expression in inflamed human...
7.
Haberland M, Montgomery R, Olson E
Nat Rev Genet
. 2008 Dec;
10(1):32-42.
PMID: 19065135
Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biological processes, largely through their repressive influence on transcription. The expression of many...
8.
Montgomery R, Potthoff M, Haberland M, Qi X, Matsuzaki S, Humphries K, et al.
J Clin Invest
. 2008 Oct;
118(11):3588-97.
PMID: 18830415
Histone deacetylase (HDAC) inhibitors show remarkable therapeutic potential for a variety of disorders, including cancer, neurological disease, and cardiac hypertrophy. However, the specific HDAC isoforms that mediate their actions are...
9.
Montgomery R, Davis C, Potthoff M, Haberland M, Fielitz J, Qi X, et al.
Genes Dev
. 2007 Jul;
21(14):1790-802.
PMID: 17639084
Histone deacetylases (HDACs) tighten chromatin structure and repress gene expression through the removal of acetyl groups from histone tails. The class I HDACs, HDAC1 and HDAC2, are expressed ubiquitously, but...
10.
Haberland M, Arnold M, McAnally J, Phan D, Kim Y, Olson E
Mol Cell Biol
. 2006 Nov;
27(2):518-25.
PMID: 17101791
Skeletal muscle development is controlled by the myocyte enhancer factor (MEF2) and myogenic basic helix-loop-helix (bHLH) families of transcription factors, which associate and synergistically activate muscle gene expression. Muscle differentiation...